HiPS-derived T Cell therapy (Minerva Biotechnologies)

N/A

Report date: 2024/11/04 15:26:16

Base Information

Drug NameHiPS-derived T Cell therapy (Minerva Biotechnologies)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMinerva Biotechnologies
China Registration ClassN/A

Develop Information

Active CompaniesMinerva Biotechnologies
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A